Business Wire

B2BROKER-GROUP

26.8.2021 15:04:33 CEST | Business Wire | Press release

Share
B2Broker Group Announces Launch of $5M USD Venture Capital Fund

B2Broker Group is pleased to officially announce the launch of its venture fund, B2Broker VC. B2Broker VC is led by a team that is one of the most successful and fast-growing financial technology groups with in-depth expertise in sectors ranging from IT development to capital management. The venture fund will enable the investment in, and nurture of external projects that are of interest such as new fintech startups and payment systems, and will create synergies for the group.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210826005497/en/

First Ventures

Back in 2017, like many other tech industry giants, B2Broker Group started working on its own internal corporate venture fund. This was focused on the development of a number of specific projects. Since then, the capitalisation of the group’s fund has grown steadily and now includes a number of projects in which the company has invested over $15 million so far. This is an exciting project which has enabled the development of a modern financial and technological ecosystem on the basis of the B2Broker group of companies.

Of particular focus is the launch of B2BinPay in 2017, a payment system which has become one of the most modern and technologically progressive platforms in the world, B2BX , a platform for the trading of digital assets which is licenced in the EU, Eqwire, a digital banking service, and last but not least, the group’s most expensive and complex project, B2Prime, which is an integrated liquidity provider with licences in different jurisdictions, including Europe and CIS.

External Projects

With the experience acquired on these internal projects and the business-processes that have been developed, B2Broker VC has also started investing in external projects. One of the most noteworthy of these is the innovative Coinsbuy, a project designed to cater for the growing demand for buying crypto using a credit or debit card. This will be a complementary project to B2Broker’s ecosystem.

Throughout this process, B2Broker VC identified the most interesting sectors such as fintech, IT development and automation, as well as startups offering products for the brokerage market.

Procedures and Stages

The most important aspect that the group seeks in its partners is conscientiousness, a clear vision and a good understanding of the market. B2Broker VC considers all potential recipients of investments as long-term strategic partners who in partnership, will move towards global leadership in the various market sectors.

B2Broker VC always finds the most convenient way of investment and cooperation both through equity holding and via convertible loans, which make the terms of cooperation as flexible as possible.

Companies who wish to apply for funding follow a step-by-step procedure starting with the preparation of an application and documents. This is followed by a product performance evaluation, follow-up questions and a series of meetings and evaluations before the final decision is made. After the signing of various documents and agreements, the first tranche of investment will be released after a process which takes between 2-6 months.

The kind of projects that are of interest to B2Broker VC are ones that match the group’s goals and business model. These include:

● Fintech development: Products and services for Forex, securities, derivatives, CFD and crypto markets.

● IT development: Development of payment systems, trading and brokerage platforms, risk management systems, analytical systems.

We are particularly interested in companies who have Bridges Technology and plugins for MT4/5, Trading Platforms for FX/CFD trading and those who have built trading platforms for Crypto Perpetual Futures, Crypto Spot trading and Securities trading on Exchanges. We are also looking for HUB and liquidity aggregation solutions and technology for market making on crypto exchanges.

● Automation: Products in the field of automation of external systems and process automation services.

● Products/services suitable for B2Broker's ecosystem such as KYC solutions, marketing services, products and services for the brokerage market.

Companies that end up working with the B2Broker Group will be handed the keys to the development of a young company that includes both financial assistance and access to the group’s infrastructure, its offices, and development teams, as well as top financial and marketing expertise.

Applications

B2Broker VC carefully considers each application received and investigates the possible mechanisms of cooperation, regardless of the size of the company and entrepreneurial experience among the founders.

To submit your application and become a global leader with B2Broker VC email us at vc@b2broker.com or visit our website .

Link:

ClickThru

Social Media:

https://www.facebook.com/b2broker

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release

Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user

Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release

Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin

Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and

Huawei, LG Electronics and Nokia Named as Founder Licensors of New Sisvel POS Pool1.4.2026 12:17:00 CEST | Press release

Three world-class innovators are the founder licensors of the new Point of Sale (POS) patent pool, covering 2G to 5G technology, which Sisvel has launched today. Huawei, LG Electronics and Nokia have made their standard essential patents (SEPs) reading on cellularly connected POS devices available through the programme, so simplifying access to the increasingly ubiquitous technology. Early participation incentives for licensors to join the pool are available until mid-May. Other cellular patent owners not currently in discussions with Sisvel are encouraged to get in touch. Ranging from handheld card machines to tablet-based registers, POS devices have transformed customer payment processing. Increasingly, they also offer enhanced capabilities such as inventory management, real-time tracking, advanced analytics and automatic re-ordering. Standardised cellular technology is the critical feature that enables POS terminals to function wherever customers are located. The Sisvel POS programm

Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D1.4.2026 11:11:00 CEST | Press release

- Medical oncologist and accomplished clinical leader brings deep development and industry experience to Mosaic’s Executive Leadership team - Vince will lead research and development for Mosaic’s drug combination programs, including the build-out of the Company’s early pipeline Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company developing next-generation, Synergistic Precision combination therapies, today announced the appointment of Dr Vince O’Neill as Head of Research and Development (R&D) to support its next phase of growth. “We are delighted to welcome Vince to the Mosaic leadership team at this pivotal stage of the company’s evolution,”said Thomas Fuchs, CEO, Mosaic Therapeutics.“His deep expertise in targeted oncology drug development and diagnostics will be instrumental as we advance our pipeline to bring transformative therapies to patients in need.” Vince is a board-certified medical oncologist and highly experienced biotechno

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye